Zynerba Pharmaceuticals, Inc. announced that it has appointed six new members of its board of directors. The appointees offer extensive scientific, regulatory commercial and financial experience and successful track records in development- and commercial-stage pharmaceutical companies. With these new appointments, Philip Wagenheim and Steve Gailar have resigned as members of the Zynerba board of directors.

The new Zynerba board appointments are: Warren D. Cooper, MB, BS, BSc, MPFM, Former CEO, Prism Pharmaceuticals; Merck, Sharp, Dohme; William J. Federici, MBA, CPA, Vice President and Chief Financial Officer of West Pharmaceutical Services; Thomas L. Harrison, LH.D, Chairman Emeritus of Diversified Agency Services; Daniel L. Kisner, MD, Former venture partner/partner, Aberdare Ventures; President and CEO, Caliper Technologies; Kenneth I. Moch, President, Euclidean Life Science Advisors; Former President and CEO, Chimerix, BioMedical Enterprises, Alteon, and Biocyte Corporation; and Cynthia Rask, MD, Former Acting Director, Office of Cellular, Tissue and Gene Therapies US Food and Drug Administration (FDA); Abbott Laboratories, Genentech.